SCHEMBL3241301

SCHEMBL3241301

COc1cc(Cl)ccc1C(=O)NC(c1ccccc1)C(C)(C)N1CCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
AVPR2 P30518 1/20 0.42
GPR27 Q9NS67 1/20 0.42
MTTP P55157 2/20 0.42
ALDH1A1 P00352 5/20 0.42
HPGD P15428 1/20 0.42
FLT1 P17948 1/20 0.42
FLT4 P35916 1/20 0.42
KDR P35968 1/20 0.42
F10 P00742 1/20 0.41
MAPT P10636 4/20 0.40
NPSR1 Q6W5P4 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.39
KDM4E B2RXH2 2/20 0.39
KCNMA1 Q12791 1/20 0.39
HIF1A Q16665 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3245923 0.88 PNLIP (0.42) MEN1KMT2AALDH1A1MAPTL3MBTL1
SCHEMBL3239516 0.85 ALDH1A1 (0.41) ALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL3236158 0.85 SLC6A9 (0.41) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL3238315 0.83 ALDH1A1 (0.41) MEN1KMT2AMTTPALDH1A1HPGD
SCHEMBL13303997 0.83 S1PR1 (0.37) MEN1KMT2AMTTPALDH1A1MAPT
SCHEMBL3238547 0.83 SMN1; SMN2 (0.48) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL3235817 0.82 TAS1R3 (0.41) MTTPALDH1A1HPGDMAPTGAA
SCHEMBL3244243 0.82 MEN1 (0.49) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL8265566 0.82 ALDH1A1 (0.42) MEN1KMT2AMTTPALDH1A1HPGD
SCHEMBL3238718 0.82 P2RX7 (0.43) ALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
WO-2006067423-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287547-A1 Glycine Transport Inhibitors SLC18A2, SLC6A5, SLC1A2 MEN1 2501/4885KMT2A 1871/4885AVPR2 322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.